The Stockholm Stock Exchange is posting a modest gain at midday on Monday, buoyed by Epiroc's earnings report, which was positively received. On the major European markets, trading in London is mixed, while Frankfurt and Paris are seeing slight declines. Later this week, several heavyweight earnings reports are expected, along with interest rate decisions from both the Federal Reserve and the Riksbank.

As of 12:30 p.m., the OMXS30 index was up 0.29 percent at 3,022.41. Shares worth approximately 7.2 billion kronor had changed hands on the Stockholm Stock Exchange.

Among the exchange's major industrial sectors, raw materials performed best, climbing 0.7 percent. On the other hand, technology lagged behind, falling by 1.3 percent.

Among the leading stocks included in the OMXS30 index, Epiroc A rose 7.2 percent, while Boliden was up 2.5 percent. The weakest performers were Addtech B, down 2.3 percent, and Saab B, which slipped 1.9 percent.

The mining and rock excavation technology company Epiroc reported adjusted operating profit and revenue for the fourth quarter that were slightly below expectations. On the positive side, order intake met consensus and showed an organic increase of 11 percent.

Contract manufacturer Note reported a higher profit in the fourth quarter of 2025 compared to the same quarter last year. Revenue declined by a couple of percent, coming in at the lower end of the company's guidance. The board proposes to scrap the dividend, compared to 7 kronor per share last year. The order backlog at year-end was 11 percent higher than at the same point the previous year for comparable units. The earnings report was well received and the share gained 4.9 percent.

Later this afternoon, industrial communications company Ependion will report. The share fell 2.6 percent ahead of the report.

Research company Bioarctic's partner Eisai received priority review from the U.S. Food and Drug Administration (FDA) for a supplemental application for Leqembi Iqlik as a subcutaneous auto-injector for weekly initiation therapy. A decision from the FDA is expected by May 24 at the latest. The share rose 0.6 percent.

Medical technology company Episurf Medical is acquiring a property portfolio from Klarabo valued at 897 million kronor. Episurf climbed 17.6 percent, while Klarabo fell 7.9 percent.

Handelsbanken upgraded its recommendation for telecom supplier Ericsson to buy from hold. The share was unchanged.

Industrial trading company Bufab rose 1.4 percent following a buy recommendation from Dagens industri.

Jefferies downgraded its recommendations for industrial companies SKF and Sandvik. The recommendation for SKF was lowered from hold to underperform, and for Sandvik from buy to hold. SKF slipped 0.5 percent, while Sandvik gained 0.8 percent.

Credit management company Intrum increased 6.4 percent after ABG Sundal Collier upgraded its recommendation to buy from hold. ABG did the opposite for residential developer JM, downgrading its recommendation to hold from buy. JM dropped 3.3 percent.

Installation company Bravida initially rose after Handelsbanken began coverage of the company with a buy recommendation, but then retreated and is now trading 0.8 percent lower.